Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

NCT01433263 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Cachexia

Interventions

DRUG: BYM338 active drug
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals